BICO, the leading Bio Convergence company, announced today it has hired Erica Bell as its first Chief People Officer. Bell most recently served as VP of Human Resources (HR) at PerkinElmer where she held various HR leadership roles supporting the global people operations across biotechnology verticals. In her new role, Bell will help develop and foster an innovative culture across BICO and its 12 group companies as the organization approaches more than 1,000 employees globally.
“BICO’s Bio Convergence agenda is unlike anything I’ve seen at other life sciences companies, and truly has the potential to transform healthcare in the coming decades,” says Erica Bell, Chief People Officer of BICO. “I’m excited to get started working with the incredible team.”
Bell first distinguished herself as a leader in HR during her 15-year tenure at GE where she oversaw various organizations in the conglomerate’s energy and healthcare portfolio. In her most recent role as VP of Human Resources at PerkinElmer, Bell supported the growth of the $4B healthcare company by leading the global HR integration and acquisition strategy.
“During this period of growth for BICO, attracting and retaining top talent will be the enabling factor in becoming a world-class life science organization,” says Erik Gatenholm, CEO, and co-founder of BICO. “I am confident that Erica will help us advance our Bio Convergence agenda and become a company that the world’s most ambitious and talented life sciences employees will want to work with.”
Bell is based out of BICO’s Boston office and will start on Tuesday, September 7, 2021. She will also be joining the company’s executive management team.
Anybody interested in helping create the Bio Convergence revolution and joining BICO’s fast growing team can visit our LinkedIn page.
For further information, please contact:
|Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
|BICO Press office
Riley Munks, PR Manager: (650) 863-6699
Alyssa D’Orazio, PR Manager: (617) 634-9601
This information was submitted for publication, through the agency of the contact persons set out above, on September 7, 2021, at 15.00 (CEST).
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com